Brief Reports
Copyright ©The Author(s) 2004.
World J Gastroenterol. Oct 1, 2004; 10(19): 2870-2873
Published online Oct 1, 2004. doi: 10.3748/wjg.v10.i19.2870
Figure 1
Figure 1 Inhibitory rates of unlabeled LHRH and 125I–LHRH on human liver cancer HEPG cell proliferation.
Figure 2
Figure 2 Saturation curve of 125I-LHRH binding to LHRHR of human liver cancer HEPG cells. TB: total binding, NB: non-specific binding, SB: specific binding.
Figure 3
Figure 3 Inhibiting curve of competitive binding of non-labeled LHRH-PE40, LHRH and TRH to human liver cancer HEPG cell LHRHR with 125I-LHRH.
Figure 4
Figure 4 Scatchard analysis of LHRH-PE40 and LHRH bind-ing to LHRHR of human liver cancer HEPG cells.
Figure 5
Figure 5 Inhibiting curve of competitive binding of non-labeled LHRH-PE40 and TRH to normal human liver cell LHRHR with 125I-LHRH.